Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease

Thyroid

Volumn 12, Issue 10, 2002, Pages 849-853

  Orgiazzi, Jacques ^a   Madec, Anne Marie ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; LEVOTHYROXINE; RADIOACTIVE IODINE; TECHNETIUM 99M; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR ANTIBODY;

AGE; ARTICLE; DISEASE SEVERITY; EYE DISEASE; FEMALE; GENDER; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LONG TERM CARE; MALE; PREDICTION; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; RELAPSE; RISK FACTOR; SMOKING; TREATMENT OUTCOME; RECURRENT DISEASE; REVIEW;

ANTITHYROID AGENTS; GRAVES DISEASE; HUMANS; RECURRENCE; RISK FACTORS;

EID: 0036808951     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072502761016467     Document Type: Article

References (19)

1. Feldt-Rasmussen U, Glinoer D, Orgiazzi J 1993 Reassessment of antithyroid drug therapy of Graves' disease. Annu Rev Med 44:323-334.
2. Allannic H, Lorcy Y, Leguerrier AM, Delambre C, Stetieh H, Madec AM, Orgiazzi J 1991 Antithyroïdiens de synthèse et maladie de Basedow ou le choix d'une stratégie thérapeutique. La Presse Médicale 20:645-651.
3. Meller J, Jauho A, Hüfner M, Gratz S, Becker W 2000 Disseminated thyroid autonomy or Graves' disease: Reevaluation by a second generation TSH receptor antibody assay. Thyroid 10:1073-1079.
4. Orgiazzi J 1987 Management of Graves' hyperthyroidism. Endocrinol Metab Clin North Am 16:365-389.
5. Orgiazzi J 2000 Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am 29:339-355.
6. Laurberg P, Buchholtz-Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J 1986 Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 111:39-43.
7. Rieu M, Raynaud A, Richard A, Laplanche S, Sambor B, Berrod JL 1994 Evidence for the effect of antibodies to TSH receptors on the thyroid ultrasonographic volume in patients with Graves' disease. Clin Endocrinol 41:667-671.
8. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 3:369-375.
9. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P 1998 The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8:119-124.
10. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, Reinwein D, the European Multicenter Study Group 1995 Response to methimazole in Graves' disease. Clin Endocrinol 43:257-263.
11. Yamamoto M, Totsuka Y, Kojima I, Yamashita N, Togawa K, Sawaki N, Ogata E 1983 Outcome of patients with Graves' disease after long-term medical treatment guided by triiodothyronine suppression test. Clin Endocrinol 19:467-476.
12. Cho BY, Shong MH, Yi KH, Lee HK, Koch CS, Min HK 1992 Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin Endocrinol 36:585-590.
13. Edan G, Massart C, Hody B, Poirier JY, Le Reun M, Hespel JP, Leclech G, Simon M 1989 Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease. BMJ 298:359-361.
14. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T 1991 Administration of thyroxine in treated Graves' disease: Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324:947-953.
15. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A 1996 Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 334:220-224.
16. Rittmaster RS, Zwicker H, Abbot EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE 1996 Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. J Clin Endocrinol Metab 81:3283-3288.
17. Feldt-Rasmussen U, Schleusener H, Carayon P 1994 Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78:98-102.
18. Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B 1996 Graves' hyperthyroidism: Treatment with antithyroid drugs, surgery or radioiodine - A prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 81:2986-2993.
19. Glinoer D, De Nayer Ph, Bex M, and the Belgian Collaborative Study Group on Graves' disease 2001 Effects of 1-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: A double-blind prospective randomized study. Eur J Endocrinol 144:475-83.